MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Study Overview
=================
Brief Summary
-----------------
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.

Official Title
-----------------
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies

Conditions
-----------------
Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

Intervention / Treatment
-----------------
* Drug: KYMRIAH
* Drug: YESCARTA
* Drug: Fludarabine 30mg/m2 4 doses
* Drug: Cyclophosphamide 500 mg/m2; 2 doses
* Drug: Fludarabine 30mg/m2 3 doses
* Drug: Cyclophosphamide 500 mg/m2; 3 doses
* Drug: Fludarabine 25mg/m2 3 days
* Drug: Cyclophosphamide 250 mg/m2; 3 days
* Drug: Tecartus
* Drug: Abecma, Intravenous Suspension
* Drug: Cyclophosphamide 900 mg/m2; 1 day
* Drug: Breyanzi Injectable Product


Participation Criteria
=================
Eligibility Criteria
-----------------
ARM A (Kymriah) and Arm G (Tecartus) :Refractory/relapsed B-cell acute lymphoblastic leukemia expressing CD19 Inclusion Criteria: Age and Disease Status Must be age 0-25 years (for Arm A Kymriah) or >18 years (Arm G Tecartus) Disease status: Relapsed and refractory pediatric B-cell ALL defined by one of these: Primary induction failure with no complete remission after ≥2 cycles of induction chemotherapy, or Patients with persistent minimal residual disease (MRD >0.01% by flow cytometry or persistent by cytogenetic or molecular assays) after ≥2 cycles of consolidation chemotherapy, or Patients in 2nd or greater relapse of B-ALL or Patients with persistent CNS leukemia, or Down Syndrome or other congenital diseases assuming that they fit the criteria for second or greater relapse or refractory leukemia, or Patients with Ph+ ALL are eligible if theywho have failed or are intolerant to two lines of TKI assuming they fit the criteria for second or greater relapse or are considered refractory. Performance Status * Arm A: Karnofsky (age ≥16 years) or Lansky (age < 16 years) performance status ≥ 50% at screening; Arm G: ECOG 0, 1 or 2 Organ Function Renal function defined as: A serum creatinine of ≤1.5 x ULN OR eGFR ≥ 50 mL/min/1.73 m2 Liver function defined as: ** ALT ≤ 5 times the ULN for age (unless due to disease) ** Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or MUGA Other Inclusion Criteria Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation) CNS 2A CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active HIV infection Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to enrollment. Patient has taken one of the prohibited concomitant medications within the timeframe outlined in section 6.1 ARM B: Yescarta for Relapsed or Refractory diffuse large B cell lymphoma Inclusion Criteria: Age and Disease Status Adult patients (age ≥ 18 years)Patients must be ≥18 years of age One of the following histologies and expression of CD19 by tumor cells: ** diffuse large B-cell lymphoma (DLBCL) not otherwise specified, or ** primary mediastinal large B-cell lymphoma, or ** high grade B-cell lymphoma, or ** DLBCL arising from follicular lymphoma Disease status: ** Chemotherapy refractory disease after ≥2 lines of chemotherapy, or ** Relapsed with no remission after ≥1 lines of salvage chemotherapy, or ** Relapsed following autologous HCT (and failed at least 2 prior lines of therapy including high dose chemotherapy). If salvage therapy is given post autoHCT, the subject must have no response or relapse after the last line of therapy Measurable disease at time of apheresis: Nodal lesions or extranodal lesion ECOG performance status 0-2 ALC >/=100/uL at screening (prior to apheresis) Renal function defined as: ** A serum creatinine of ≤1.5 x ULN OR ** eGFR ≥ 50 mL/min/1.73 m2 Liver function defined as: ALT ≤ 5 times the ULN for age (unless due to disease) Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or MUGA Adequate bone marrow reserve (unless marrow infiltrated by disease) defined as : Absolute neutrophil count (ANC) > 1.000/mm3 (only for NHL) Platelets ≥ 50.000/mm3 (transfusion support can be provided) Hemoglobin >8.0 mg/dl (transfusion support can be provided) Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Active CNS involvement by malignancy (no evidence of disease in CSF by flow cytometry) CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active HIV infection (controlled HIV is permissible) Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to apheresis. Patient has taken one of the prohibited concomitant medications within the timeframe. ARM C: Kymriah for rRelapsed or rRefractory diffuse large B cell lymphoma Inclusion Criteria: Age and Disease Status Adult patients (age ≥ 18 years) with relapsed or refractory (r/r) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Disease status: after two or more lines of systemic therapy or relapse after autologous HCT Performance Status ECOG performance status 0-2 ALC >/=100/uL at screening (prior to apheresis) Organ Function Renal function defined as: A serum creatinine of ≤1.5 x ULN OR eGFR ≥ 50 mL/min/1.73 m^2 Liver function defined as: ALT ≤ 5 times the ULN for age (unless due to disease) Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or MUGA Adequate bone marrow reserve (unless marrow infiltrated by disease) defined as : Absolute neutrophil count (ANC) > 1.000/mm3 (only for NHL) Platelets ≥ 50.000/mm3 (transfusion support can be provided) Hemoglobin >8.0 mg/dl (transfusion support can be provided) Other Inclusion Criteria Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Active CNS involvement by malignancy (no evidence of disease in CSF by flow cytometry) CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active or inactive HIV infection Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to apheresis. Patient has taken one of the prohibited concomitant medications within the timeframe ARM D: Tecartus (Brexucabtagene Autoleucel) for relapsed or refractory mantle cell lymphoma Inclusion Criteria: Age and Disease Status * with relapsed or refractory (r/r) mantle cell lymphoma, including prior anthracycline or Bendamustine containing therapy prior Rituximab or other CD20 directed antibody (or inability to treat with CD20 MoAb) not a candidate or relapse after autologous HCT active disease at enrollment Performance Status *ECOG performance status 0-1 Organ Function Renal function defined as: A serum creatinine of ≤1.5 x ULN OR eGFR ≥ 50 mL/min/1.73 m2 Liver function defined as: ALT ≤ 5 times the ULN for age (unless due to disease) Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or MUGA Adequate bone marrow reserve (unless marrow infiltrated by disease) defined as: Absolute neutrophil count (ANC) > 1,000/mm^3 (only for NHL) Platelets ≥ 50,000/mm^3 (transfusion support can be provided) Hemoglobin >8.0 mg/dl (transfusion support can be provided) Other Inclusion Criteria: Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. See section 4.5 for definitions of child bearing potential and section 4.6 for definitions of adequate birth control. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Active CNS involvement by malignancy (no evidence of disease in CSF by flow cytometry) CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active HIV infection Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to apheresis (steroids must be stopped >72 hours prior to apheresis). Patient has taken one of the prohibited concomitant medications within the timeframe ARM E: Breyanzi lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma Inclusion Criteria: Age and Disease Status Adult patients (age ≥ 18 years) with relapsed or refractory disease after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma grade 3B Performance Status *ECOG performance status 0-2 Organ Function Renal function defined as: A serum creatinine of ≤1.5 x ULN OR eGFR ≥ 30 mL/min/1.73 m2 Liver function defined as: ALT ≤ 5 times the ULN for age (unless due to disease) Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 40% confirmed by echocardiogram or MUGA Adequate bone marrow reserve (unless marrow infiltrated by disease) defined as: Absolute neutrophil count (ANC) > 1,000/mm^3 (only for NHL) Platelets ≥ 50,000/mm^3 (transfusion support can be provided) Hemoglobin >8.0 mg/dl (transfusion support can be provided) Other Inclusion Criteria: Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. See section 4.5 for definitions of child bearing potential and section 4.6 for definitions of adequate birth control. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Active CNS involvement by malignancy (no evidence of disease in CSF by flow cytometry) CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active HIV infection Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to apheresis (steroids must be stopped >72 hours prior to apheresis). Patient has taken one of the prohibited concomitant medications within the timeframe ARM F: Abecma Idecabtagene Vicleucel for relapsed or refractory multiple myeloma Inclusion Criteria: Age and Disease Status Adult patients (age ≥ 18 years) Relapsed (progression after prior partial or complete remission) or refractory multiple myeloma Evidence of active disease (medullary or extramedullary) Prior therapy (Failure or intolerance to) with an immunomodulatory agent, a proteasome inhibitor, and an antiCD38 monoclonal antibody Performance Status *ECOG performance status 0-1 Organ Function Renal function defined as: A serum creatinine of ≤2 x ULN OR eGFR ≥ 50 mL/min/1.73 m2 Liver function defined as: ALT ≤ 5 times the ULN for age (unless due to disease) Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation SpO2 > 91% on room air Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or MUGA Adequate bone marrow reserve (unless marrow infiltrated by disease) defined as: Absolute neutrophil count (ANC) > 1,000/mm^3 (only for NHL) Platelets ≥ 50,000/mm^3 (transfusion support can be provided) Hemoglobin >8.0 mg/dl (transfusion support can be provided) Other Inclusion Criteria: Life expectancy ≥12 weeks Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment. See section 4.5 for definitions of child bearing potential and section 4.6 for definitions of adequate birth control. Written voluntary consent (adults) or parental/guardian consent (minors or adults with diminished capacity) prior to the performance of any research related tests or procedures. Exclusion Criteria: Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. Active CNS involvement by malignancy (no evidence of disease in CSF by flow cytometry) CAR-T is not indicated for the treatment of patients with primary central nervous system lymphoma. Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). All GVHD medication must be stopped 2 weeks prior to apheresis. Uncontrolled active hepatitis B or hepatitis C Active HIV infection Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion) Unstable angina and/or myocardial infarction within 1 month prior to CAR-T infusion Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion Intolerance to the excipients of the CAR-T cell product Any immunosuppressive medication must be stopped ≥ 2 weeks prior to apheresis (steroids must be stopped >72 hours prior to apheresis). Patient has taken one of the prohibited concomitant medications within the timeframe
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)<br> | Drug: KYMRIAH<br>* FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells<br>* Other names: tisagenlecleucel;Drug: Fludarabine 30mg/m2 4 doses<br>* 30 mg/m2 IV daily for 4 doses<br>Drug: Cyclophosphamide 500 mg/m2; 2 doses<br>* 500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine<br>|
| ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)<br> | Drug: YESCARTA<br>* CD19-directed genetically modified autologous T cell immunotherapy<br>Drug: Fludarabine 30mg/m2 3 doses<br>* 30 mg/m2 IV daily for 3 doses<br>Drug: Cyclophosphamide 500 mg/m2; 3 doses<br>* 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine<br>|
| ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)<br> | Drug: KYMRIAH<br>* FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells<br>* Other names: tisagenlecleucel;Drug: Fludarabine 25mg/m2 3 days<br>* 25 mg/m2 i.v. daily for 3 days<br>Drug: Cyclophosphamide 250 mg/m2; 3 days<br>* 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine<br>|
| Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)<br> | Drug: Fludarabine 30mg/m2 3 doses<br>* 30 mg/m2 IV daily for 3 doses<br>Drug: Cyclophosphamide 500 mg/m2; 3 doses<br>* 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine<br>Drug: Tecartus<br>* TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells<br>* Other names: Brexucabtagene Autoleucel;|
| Arm E: Breyanzi for relapsed or refractory large B-cell lymphoma (RLBCL)<br> | Drug: Fludarabine 30mg/m2 3 doses<br>* 30 mg/m2 IV daily for 3 doses<br>Drug: Cyclophosphamide 500 mg/m2; 3 doses<br>* 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine<br>Drug: Breyanzi Injectable Product<br>* Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.<br>|
| Arm F: Abecma for relapsed or refractory multiple myeloma<br> | Drug: Fludarabine 30mg/m2 3 doses<br>* 30 mg/m2 IV daily for 3 doses<br>Drug: Cyclophosphamide 500 mg/m2; 3 doses<br>* 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine<br>Drug: Abecma, Intravenous Suspension<br>* Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.<br>|
| Arm G: Tecartus B-cell acute lymphoblastic leukemia (ALL)<br> | Drug: Fludarabine 25mg/m2 3 days<br>* 25 mg/m2 i.v. daily for 3 days<br>Drug: Tecartus<br>* TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells<br>* Other names: Brexucabtagene Autoleucel;Drug: Cyclophosphamide 900 mg/m2; 1 day<br>* Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arm A&G: Complete Remission (CR) | Incidence of CR | Day 28 | 
| Arm A&G: CRi (complete remission without count recovery) | Incidence of CRi | Day 28 | 
| Arms B & C&D& E&F: Overall Response Rate (ORR) | ORR defined by complete response + partial response by Lugano | Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arm A: MRD-negative CR (or CRi) | Proportion of patients with MRD-negative CR (or CRi) | Day 28 | 
| Arm A: Proportion of patients who are alive but not in remission | Proportion of patients who are alive but not in remission | Day 28 | 
| Treatment Related Mortality (TRM) | Incidence of treatment related mortality (in absence of disease relapse/progression) | Day 28 | 
| Treatment Related Mortality (TRM) | Incidence of treatment related mortality (in absence of disease relapse/progression) | Day 100 | 
| Treatment Related Mortality (TRM) | Incidence of treatment related mortality (in absence of disease relapse/progression) | 1 Year | 
| Relapse-free Survival (RFS) | Incidence of Relapse-free Survival (RFS) | At complete remission to relapse or death | 
| Event-Free Survival (EFS) | Incidence of event-free survival (EFS) from the date of the CAR-T infusion through 1 year post treatment | 1 Year post treatment | 
| Overall Survival (OS) | Incidence of Overall Survival (OS) from the date of the CAR-T infusion through the date of patient death for any reason. | Date of Death | 
| Toxicity | Proportion of patients with grade 3 or 4 targeted toxicity of CRS and/or neurotoxicity | Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ALL, CAR-T, CAR19-T, chimeric antigen receptor T cells